Cargando…
Treatment of myocardial interstitial fibrosis in pathological myocardial hypertrophy
Pathological myocardial hypertrophy can be caused by a variety of diseases, mainly accompanied by myocardial interstitial fibrosis (MIF), which is a diffuse and patchy process, appearing as a combination of interstitial micro-scars and perivascular collagen fiber deposition. Different stimuli may tr...
Autores principales: | Zhu, Fuyu, Li, Peng, Sheng, Yanhui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561344/ https://www.ncbi.nlm.nih.gov/pubmed/36249793 http://dx.doi.org/10.3389/fphar.2022.1004181 |
Ejemplares similares
-
Dangshen Erling Decoction Ameliorates Myocardial Hypertrophy via Inhibiting Myocardial Inflammation
por: Zhong, Yigang, et al.
Publicado: (2022) -
Does Transient Receptor Potential Vanilloid Type 1 Alleviate or Aggravate Pathological Myocardial Hypertrophy?
por: Yan, Qiqi, et al.
Publicado: (2021) -
Drugs for treating myocardial fibrosis
por: Ren, Zhanhong, et al.
Publicado: (2023) -
Non-invasive assessment of interstitial myocardial fibrosis in pressure-overload left ventricular hypertrophy
por: Jabbour, Andrew, et al.
Publicado: (2012) -
Hydrogen Sulfide Inhibits High-Salt Diet-Induced Myocardial Oxidative Stress and Myocardial Hypertrophy in Dahl Rats
por: Huang, Pan, et al.
Publicado: (2017)